|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Cancer Overview - Increasing Collaboration to Accommodate Increasing Fragmentation
Datamonitor, Jan 2003, Pages: 205
Introduction
The global cancer market is predicted to be worth around $20 billion in 2003, and is expected to increase to over $45 billion by 2011. Over the next decade, advances in the pharmacotherapy of cancer will come not only from improvements in the traditional classes of therapies, but also from introduction of innovative therapies that display improved efficacy and toxicity through a targeted approach.
Scope
Patient potential of the ten major tumor types, including key trends in their epidemiology and reviews of their current treatment methods
Data for the following cancers: breast, prostate, lung, colorectal, ovarian, brain, pancreatic, head and neck, leukemia and malignant melanoma
Company oncology pipeline analysis of Aventis, Roche, and Bristol-Myers Squibb
Analysis of the phase III drugs, including clinical trial data and descriptions of their market potential, with sales forecasts to 2011 for key drugs
Report Highlights
Datamonitor predicts that the 10 major tumor types covered in this report will be responsible for the deaths of over 1.25 million people in 2003 within the seven major markets. The size of the cancer problem is reflected by the size of the global cancer market, which is predicted to be worth around $20 billion in 2003.
The traditional treatment classes including cytotoxic and hormonal therapies will continue to form the backbone of standard cancer therapy, and hence should continue to achieve strong sales in the short-term.
Reasons to Purchase
Assess competitive threat from novel compounds entering the cancer market
Characterize saturated and under-served markets in cancer
Find potential out-licensing and co-marketing partners in the cancer market
Report Highlights
The cancer market will see continued strong growth of the innovatives classes of therapies. Pharmaceutical companies should invest in the development or in-licensing of innovative cancer treatments to maintain market share. The key to the success of an innovative therapy is synergy with traditional therapies.
Customers who bought this item also bought
Drugs of Tomorrow: Cancer Overview
Drugs of Tomorrow: Cancer Overview - The synergistic advance: innovatives compliment traditional chemotherapies
Pipeline Insight: Cancer Overview - Increasing Collaboration to Accommodate Increasing Fragmentation
Drugs of Tomorrow 2001: Cancer Overview
The 2009 World Forecasts of Butadiene Rubber (BR) Export Supplies
The 2009 World Market Forecasts for Imported Butadiene Rubber (BR)
Pipeline Insight: Prostate Cancer - Domination By The Innovative Classes
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Drugs of Tomorrow 2000: Prostate Cancer - Hormonals and Beyond
Drug Delivery in Cancer - Technologies, Markets and Companies
Cancer Therapies - Global Strategic Business Report
Treatment Algorithms 2001: Prostate Cancer
|
|
|
|
